Drug Profile

VAXinia

Alternative Names: CF-33; CF-33 hNIS

Latest Information Update: 18 Nov 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Imugene
Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
Mechanism of Action Cell death stimulants; Immunologic cytotoxicity; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Cholangiocarcinoma
New Molecular Entity No

Highest Development Phases

Phase I Solid tumours

Most Recent Events

05 Nov 2024 Imugene receives patent extension in USA
24 Sep 2024 VAXinia receives Orphan Drug status for Cholangiocarcinoma in USA
09 Apr 2024 Pharmacodynamics data from a phase I trial in Solid tumors released by Imugene

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com